Company: BGLC
Filing Date: 2025-11-12
Form Type: 8-K
Source: 0001477932-25-008044
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-12
Form: 8-K
Item: Item 3.02
Chunk 2
---
Item 3.02. Unregistered Sales of Equity Securities.

The information described in Item 1.01 above is hereby incorporated by reference. In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares. The issuance will be made in an offshore transaction in reliance upon Regulation S under the Securities Act of 1933, as amended (the “ Securities Act”). The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.

Item 7.01. Regulation FD Disclosure.